

PFIZER INC. AND SUBSIDIARY COMPANIES
RECASTED PRODUCT REVENUES TABLES
SUPPLEMENTAL INFORMATION

Pfizer is providing the attached recasted unaudited historical product revenues tables for each of the quarters and full year 2025 to conform to Pfizer's new commercial operating structure, as of January 1, 2026, which reflects the transition of certain off-patent branded and generic sterile injectables and biosimilars primarily from the Specialty Care and Oncology product portfolios to a new Hospital and Biosimilars product portfolio within the Global Biopharmaceuticals Business (Biopharma) reportable segment. Effective January 1, 2026, the commercial structure within the Biopharma reportable segment is as follows:

- Pfizer U.S. Commercial Division, which includes the U.S. commercial organization covering Pfizer's entire product portfolio except for the Global Hospital and Biosimilars organization.
- Pfizer International Commercial Division, which includes the ex-U.S. commercial organizations covering Pfizer's entire product portfolio in all international markets except for the Global Hospital and Biosimilars organization in certain international markets.
- Global Hospital and Biosimilars Division, which includes the commercial organization covering Pfizer's Hospital and Biosimilars product portfolio of off-patent branded and generic sterile injectables and biosimilars except in China, Hong Kong, and certain other international markets.

The new commercial structure within Biopharma is designed to better support and optimize performance across the product portfolios: Primary Care, Specialty Care, Oncology, and beginning in 2026 the Hospital and Biosimilars product portfolio. Prior-period amounts reflected in the 2025 Product Revenues Tables have been recasted to conform to the current presentation. These changes have no impact on our previously reported consolidated revenues or net income.

For additional information regarding the changes in Pfizer's commercial operating structure, see the Item 1. Business—Commercial Operations section of Pfizer's 2025 Annual Report on Form 10-K (available at www.pfizer.com and www.sec.gov), Pfizer's first quarter 2026 earnings release once it is furnished on Form 8-K with the U.S. Securities and Exchange Commission (SEC), which is expected to be on or about May 5, 2026, and Pfizer's Quarterly Report on Form 10-Q for the quarterly period ended March 29, 2026 once it is filed with the SEC, which is expected to be on or about May 5, 2026.

PFIZER INC. REVENUES
FIRST QUARTER 2025 and 2024
UNAUDITED
(millions of dollars)

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL			
	2025	2024	% Change		2025	2024	Total	2025	2024	% Change	
			Total	Oper.						Total	Total
TOTAL REVENUES	\$ 13,715	\$ 14,879	(8%)	(6%)	\$ 8,374	\$ 9,514	(12%)	\$ 5,341	\$ 5,365	—	4%
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)^(a)	\$ 13,441	\$ 14,604	(8%)	(6%)	\$ 8,285	\$ 9,426	(12%)	\$ 5,156	\$ 5,178	—	4%
Primary Care	\$ 5,692	\$ 7,206	(21%)	(20%)	\$ 3,577	\$ 5,094	(30%)	\$ 2,115	\$ 2,112	—	5%
Eliquis ^(b)	1,923	2,040	(6%)	(4%)	1,299	1,413	(8%)	624	626	—	5%
Prevnar family ^(c)	1,660	1,691	(2%)	(1%)	1,170	1,149	2%	491	542	(9%)	(6%)
Comirnaty	565	354	60%	62%	229	118	94%	335	236	42%	45%
Paxlovid ^(d)	491	2,035	(76%)	(75%)	347	1,800	(81%)	145	234	(38%)	(35%)
Nurtec ODT/Vydura	248	178	40%	40%	228	167	36%	20	10	*	*
Abrysvo	131	145	(9%)	(6%)	63	131	(52%)	68	14	*	*
All other Primary Care	672	765	(12%)	(9%)	240	315	(24%)	432	450	(4%)	1%
Specialty Care	\$ 2,616	\$ 2,406	9%	11%	\$ 1,367	\$ 1,258	9%	\$ 1,249	\$ 1,148	9%	14%
Vyndaqel family ^(e)	1,486	1,137	31%	33%	986	751	31%	499	386	29%	36%
Enbrel (Outside the U.S. and Canada)	140	159	(12%)	(6%)	—	—	—	140	159	(12%)	(6%)
Zavicefca (Outside the U.S. and Canada)	135	125	8%	14%	—	—	—	135	125	8%	14%
Xeljanz	128	194	(34%)	(31%)	20	74	(73%)	108	120	(10%)	(6%)
Cibinqo	58	42	39%	42%	24	23	2%	34	19	85%	91%
All other Specialty Care	669	749	(11%)	(8%)	336	409	(18%)	332	340	(2%)	3%
Oncology	\$ 3,494	\$ 3,285	6%	8%	\$ 2,629	\$ 2,412	9%	\$ 866	\$ 873	(1%)	4%
Ibrance	977	1,054	(7%)	(6%)	659	679	(3%)	318	375	(15%)	(10%)
Xtandi ^(f)	458	418	9%	9%	458	418	9%	—	—	—	—
Padcev	426	341	25%	25%	419	334	25%	7	7	—	2%
Lorbrena	222	164	36%	39%	92	59	55%	130	104	25%	29%
Inlyta	219	237	(7%)	(6%)	129	141	(8%)	90	96	(6%)	(2%)
Adcetris ^(g)	218	257	(15%)	(15%)	213	252	(16%)	5	5	(9%)	(3%)
Bosulif	151	145	4%	5%	120	101	18%	31	44	(29%)	(25%)
Braftovi/Mektovi	136	116	17%	17%	128	111	15%	8	5	53%	65%
Aromasin	108	82	31%	34%	—	1	(22%)	107	82	31%	34%
Tukysa	102	106	(3%)	(3%)	83	89	(7%)	20	17	16%	21%
Elrexfo	60	13	*	*	31	11	*	29	2	*	*
Talzena	40	23	74%	77%	29	17	69%	11	6	89%	99%
Tivdak	33	28	21%	22%	31	27	12%	3	—	*	*
All other Oncology	345	301	15%	17%	238	171	39%	107	130	(17%)	(13%)
Hospital and Biosimilars^(a)	\$ 1,639	\$ 1,706	(4%)	(1%)	\$ 713	\$ 661	8%	\$ 926	\$ 1,045	(11%)	(7%)
Oncology biosimilars ⁽ⁱ⁾	264	264	—	2%	177	160	11%	87	104	(17%)	(11%)
Sulperazon (Outside the U.S. and Canada)	164	167	(2%)	—	—	—	—	164	167	(2%)	—
Infectra	153	158	(3%)	(2%)	103	96	7%	50	62	(19%)	(15%)
Zithromax	158	200	(21%)	(18%)	—	—	(37%)	158	199	(21%)	(18%)
All other Hospital and Biosimilars	901	917	(2%)	1%	433	405	7%	468	512	(9%)	(3%)
Pfizer CentreOne^(j)	\$ 257	\$ 258	—	2%	\$ 72	\$ 71	2%	\$ 185	\$ 187	(1%)	2%
Pfizer Ignite	\$ 17	\$ 17	(3%)	(3%)	\$ 17	\$ 17	(3%)	\$ —	\$ —	—	—
Biopharma	\$ 13,441	\$ 14,604	(8%)	(6%)	\$ 8,285	\$ 9,426	(12%)	\$ 5,156	\$ 5,178	—	4%
PFIZER U.S. COMMERCIAL DIVISION	7,572	8,764	(14%)	(14%)	7,572	8,764	(14%)	—	—	—	—
PFIZER INTERNATIONAL COMMERCIAL DIVISION	4,849	4,818	1%	5%	—	—	—	4,849	4,818	1%	5%
GLOBAL HOSPITAL AND BIOSIMILARS DIVISION ^(k)	1,020	1,021	—	2%	713	661	8%	307	360	(15%)	(9%)
Total Alliance revenues included above	\$ 2,113	\$ 2,172	(3%)	(2%)	\$ 1,727	\$ 1,780	(3%)	\$ 386	\$ 392	(1%)	3%
Total Royalty revenues included above	\$ 308	\$ 263	17%	17%	\$ 305	\$ 263	16%	\$ 3	\$ —	*	*

PFIZER INC. REVENUES
SECOND QUARTER 2025 and 2024
UNAUDITED
(millions of dollars)

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL			
	2025	2024	% Change		2025	2024	% Change	2025	2024	% Change	
			Total	Oper.						Total	Total
TOTAL REVENUES	\$ 14,653	\$ 13,283	10%	10%	\$ 8,894	\$ 7,892	13%	\$ 5,759	\$ 5,391	7%	6%
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)^(a)	\$ 14,305	\$ 12,991	10%	10%	\$ 8,793	\$ 7,828	12%	\$ 5,512	\$ 5,163	7%	6%
Primary Care	\$ 5,535	\$ 4,947	12%	12%	\$ 3,430	\$ 2,938	17%	\$ 2,105	\$ 2,009	5%	4%
Eliquis ^(b)	2,003	1,877	7%	6%	1,322	1,262	5%	681	615	11%	8%
Prevnar family ^(c)	1,383	1,359	2%	2%	860	832	3%	523	527	(1%)	—
Paxlovid	427	251	70%	71%	328	68	*	99	184	(46%)	(45%)
Comirnaty	381	195	96%	95%	176	58	*	205	137	49%	49%
Nurtec ODT/Vydura	359	356	1%	1%	333	339	(2%)	25	17	48%	47%
Abrysvo	143	56	*	*	101	41	*	42	15	*	*
FSME-IMMUN/TicoVac	109	100	9%	6%	1	1	16%	108	99	9%	6%
All other Primary Care	731	754	(3%)	(3%)	308	337	(9%)	423	416	2%	2%
Specialty Care	\$ 3,089	\$ 2,821	9%	9%	\$ 1,561	\$ 1,506	4%	\$ 1,527	\$ 1,315	16%	15%
Vyndaqel family ^(c)	1,615	1,323	22%	21%	990	861	15%	626	462	35%	32%
Xeljanz	322	303	6%	6%	206	181	14%	115	122	(5%)	(6%)
Zavicefta (Outside the U.S. and Canada)	163	150	9%	10%	—	—	—	163	150	9%	10%
Enbrel (Outside the U.S. and Canada)	154	179	(14%)	(14%)	—	—	—	154	179	(14%)	(14%)
Genotropin	106	119	(10%)	(10%)	18	28	(37%)	89	91	(2%)	(1%)
Cresamba	111	71	56%	55%	—	—	—	111	71	56%	55%
Cibinqo	69	47	47%	46%	24	15	59%	44	32	41%	40%
All other Specialty Care	549	629	(13%)	(12%)	323	421	(23%)	225	208	8%	10%
Oncology	\$ 4,034	\$ 3,677	10%	10%	\$ 3,021	\$ 2,741	10%	\$ 1,014	\$ 936	8%	8%
Ibrance	1,049	1,130	(7%)	(8%)	696	741	(6%)	353	390	(9%)	(11%)
Xtandi ^(d)	566	495	14%	14%	566	495	14%	—	—	—	—
Padcev	542	394	38%	38%	534	387	38%	7	7	9%	11%
Lorbrena	251	169	49%	48%	100	70	43%	151	99	53%	52%
Adcetris ^(e)	255	279	(9%)	(9%)	248	271	(9%)	6	7	(11%)	(9%)
Inlyta	243	252	(4%)	(4%)	132	151	(13%)	111	101	9%	10%
Braflovi/Mektovi	182	148	23%	23%	171	142	21%	10	6	60%	67%
Bosulif	149	167	(11%)	(12%)	116	118	(1%)	32	49	(34%)	(36%)
Tukysa	132	121	9%	8%	107	97	11%	24	24	—	(2%)
Aromasin	111	87	27%	28%	1	1	(10%)	111	87	27%	28%
Elrexifio	85	22	*	*	35	18	96%	50	5	*	*
Talzenna	46	32	44%	43%	34	25	37%	12	7	67%	62%
Tivdak	46	33	39%	38%	43	32	34%	2	1	*	*
All other Oncology	380	347	10%	10%	237	194	22%	143	153	(7%)	(6%)
Hospital and Biosimilars^(a)	\$ 1,647	\$ 1,546	7%	7%	\$ 781	\$ 643	21%	\$ 866	\$ 902	(4%)	(3%)
Oncology biosimilars ^(f)	353	279	26%	27%	257	177	45%	97	103	(6%)	(5%)
Sulperazon (Outside the U.S. and Canada)	166	144	15%	16%	—	—	—	166	144	15%	16%
Infectra	139	97	43%	43%	100	43	*	39	54	(28%)	(26%)
Zithromax	56	74	(25%)	(25%)	—	—	*	56	74	(25%)	(25%)
All other Hospital and Biosimilars	934	951	(2%)	(1%)	425	423	*	509	528	(4%)	(3%)
Pfizer CentreOne^(g)	\$ 328	\$ 278	18%	18%	\$ 81	\$ 49	65%	\$ 247	\$ 229	8%	8%
Pfizer Ignite	\$ 20	\$ 15	38%	38%	\$ 20	\$ 15	38%	\$ —	\$ —	—	—
Biopharma	\$ 14,305	\$ 12,991	10%	10%	\$ 8,793	\$ 7,828	12%	\$ 5,512	\$ 5,163	7%	6%
PFIZER U.S. COMMERCIAL DIVISION	8,011	7,185	12%	12%	8,011	7,185	12%	—	—	—	—
PFIZER INTERNATIONAL COMMERCIAL DIVISION	5,178	4,804	8%	7%	—	—	—	5,178	4,804	8%	7%
GLOBAL HOSPITAL AND BIOSIMILARS DIVISION ^(h)	1,116	1,002	11%	11%	781	643	21%	334	359	(7%)	(7%)
Total Alliance revenues included above	\$ 2,273	\$ 2,067	10%	9%	\$ 1,837	\$ 1,680	9%	\$ 437	\$ 387	13%	10%
Total Royalty revenues included above	\$ 426	\$ 345	23%	23%	\$ 423	\$ 344	23%	\$ 3	\$ 2	58%	53%

PFIZER INC. REVENUES
SIX MONTHS 2025 and 2024
UNAUDITED
(millions of dollars)

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL			
	2025	2024	% Change		2025	2024	% Change	2025	2024	% Change	
			Total	Oper.						Total	Total
TOTAL REVENUES	\$ 28,367	\$ 28,162	1%	2%	\$ 17,268	\$ 17,406	(1%)	\$ 11,100	\$ 10,756	3%	5%
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)^(a)	\$ 27,746	\$ 27,595	1%	1%	\$ 17,078	\$ 17,254	(1%)	\$ 10,668	\$ 10,341	3%	5%
Primary Care	\$ 11,226	\$ 12,154	(8%)	(7%)	\$ 7,006	\$ 8,032	(13%)	\$ 4,220	\$ 4,121	2%	4%
Eliquis ^(b)	3,926	3,917	—	1%	2,621	2,675	(2%)	1,305	1,242	5%	7%
Prevnar family ^(c)	3,043	3,050	—	—	2,030	1,981	2%	1,013	1,069	(5%)	(3%)
Comirnaty	945	548	72%	74%	406	176	*	540	373	45%	47%
Paxlovid ^(d)	918	2,286	(60%)	(59%)	675	1,868	(64%)	244	418	(42%)	(39%)
Nurtec ODT/Vydura	607	533	14%	14%	561	506	11%	46	27	68%	69%
Abrysvo	274	201	36%	39%	164	172	(5%)	110	29	*	*
FSME-IMMUN/TicoVac	172	165	4%	4%	2	2	1%	170	163	4%	4%
All other Primary Care	1,340	1,453	(8%)	(6%)	547	652	(16%)	793	801	(1%)	2%
Specialty Care	\$ 5,705	\$ 5,227	9%	10%	\$ 2,928	\$ 2,764	6%	\$ 2,772	\$ 2,463	13%	15%
Vyndaqel family ^(c)	3,101	2,460	26%	27%	1,976	1,612	23%	1,125	848	33%	34%
Xeljanz	450	497	(10%)	(9%)	226	255	(11%)	223	242	(8%)	(6%)
Zavicefta (Outside the U.S. and Canada)	299	275	8%	12%	—	—	—	299	275	8%	12%
Enbrel (Outside the U.S. and Canada)	294	338	(13%)	(10%)	—	—	—	294	338	(13%)	(10%)
Genotropin	201	239	(16%)	(13%)	29	58	(51%)	172	181	(5%)	(1%)
Cresamba	184	146	26%	27%	—	—	—	184	146	26%	27%
Cibinqo	127	89	43%	44%	48	38	25%	79	50	57%	59%
All other Specialty Care	1,050	1,183	(11%)	(10%)	649	800	(19%)	401	384	5%	8%
Oncology	\$ 7,528	\$ 6,962	8%	9%	\$ 5,649	\$ 5,154	10%	\$ 1,879	\$ 1,808	4%	6%
Ibrance	2,026	2,184	(7%)	(7%)	1,354	1,420	(5%)	671	765	(12%)	(11%)
Xtandi ^(f)	1,023	913	12%	12%	1,023	913	12%	—	—	—	—
Padcev	967	735	32%	32%	953	721	32%	14	14	5%	6%
Lorbrena	473	332	42%	44%	192	129	49%	281	203	38%	40%
Adcetris ^(g)	472	536	(12%)	(12%)	461	524	(12%)	11	12	(10%)	(7%)
Inlyta	462	489	(6%)	(5%)	261	292	(11%)	201	197	2%	4%
Braflovi/Mektovi	317	264	20%	21%	299	252	19%	18	12	57%	66%
Bosulif	300	313	(4%)	(4%)	236	219	8%	64	93	(32%)	(31%)
Tukysa	234	227	3%	3%	190	186	2%	44	41	6%	7%
Aromasin	219	170	29%	31%	1	1	(16%)	218	169	29%	31%
Elrexifio	145	35	*	*	66	29	*	79	6	*	*
Talzenna	86	55	56%	57%	63	42	50%	23	13	77%	78%
Tivdak	79	60	31%	31%	74	60	24%	5	1	*	*
All other Oncology	725	648	12%	13%	475	365	30%	250	283	(12%)	(9%)
Hospital and Biosimilars^(h)	\$ 3,286	\$ 3,252	1%	3%	\$ 1,494	\$ 1,304	15%	\$ 1,792	\$ 1,948	(8%)	(5%)
Oncology biosimilars ⁽ⁱ⁾	617	543	14%	15%	434	336	29%	183	207	(12%)	(8%)
Sulperazon (Outside the U.S. and Canada)	330	311	6%	7%	—	—	—	330	311	6%	7%
Infectra	291	255	14%	15%	202	140	45%	89	116	(23%)	(20%)
Zithromax	213	274	(22%)	(20%)	—	—	(75%)	213	274	(22%)	(20%)
All other Hospital and Biosimilars	1,835	1,868	(2%)	—	858	828	4%	977	1,040	(6%)	(3%)
Pfizer CentreOne^(j)	\$ 585	\$ 535	9%	10%	\$ 153	\$ 120	28%	\$ 432	\$ 416	4%	5%
Pfizer Ignite	\$ 37	\$ 32	16%	16%	\$ 37	\$ 32	16%	\$ —	\$ —	—	—
Biopharma	\$ 27,746	\$ 27,595	1%	1%	\$ 17,078	\$ 17,254	(1%)	\$ 10,668	\$ 10,341	3%	5%
PFIZER U.S. COMMERCIAL DIVISION	15,583	15,950	(2%)	(2%)	15,583	15,950	(2%)	—	—	—	—
PFIZER INTERNATIONAL COMMERCIAL DIVISION	10,027	9,622	4%	6%	—	—	—	10,027	9,622	4%	6%
GLOBAL HOSPITAL AND BIOSIMILARS DIVISION ^(k)	2,136	2,023	6%	7%	1,494	1,304	15%	641	719	(11%)	(8%)
Total Alliance revenues included above	\$ 4,386	\$ 4,240	3%	4%	\$ 3,563	\$ 3,461	3%	\$ 823	\$ 779	6%	7%
Total Royalty revenues included above	\$ 734	\$ 608	21%	21%	\$ 728	\$ 606	20%	\$ 6	\$ 2	*	*

PFIZER INC. REVENUES
THIRD QUARTER 2025 and 2024
UNAUDITED
(millions of dollars)

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL			
	2025	2024	% Change		2025	2024	% Change	2025	2024	% Change	
			Total	Oper.						Total	Total
TOTAL REVENUES	\$ 16,654	\$ 17,702	(6%)	(7%)	\$ 10,691	\$ 12,064	(11%)	\$ 5,963	\$ 5,638	6%	2%
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)^(a)	\$ 16,310	\$ 17,392	(6%)	(7%)	\$ 10,599	\$ 11,964	(11%)	\$ 5,711	\$ 5,428	5%	2%
Primary Care	\$ 7,642	\$ 9,054	(16%)	(16%)	\$ 5,343	\$ 6,767	(21%)	\$ 2,299	\$ 2,287	—	(3%)
Eliquis ^(b)	2,015	1,617	25%	22%	1,292	1,002	29%	723	616	17%	11%
Prevnar family ^(c)	1,742	1,803	(3%)	(4%)	1,155	1,308	(12%)	587	495	18%	17%
Paxlovid ^(d)	1,225	2,703	(55%)	(55%)	1,122	2,313	(52%)	104	389	(73%)	(73%)
Comirnaty	1,151	1,422	(19%)	(20%)	870	1,164	(25%)	282	258	9%	5%
Nurtec ODT/Vydura	412	337	22%	22%	383	314	22%	29	23	26%	22%
Abrysvo	279	356	(22%)	(22%)	210	318	(34%)	68	38	81%	75%
FSME-IMMUN/TicoVac	100	81	24%	15%	1	1	81%	99	80	23%	15%
All other Primary Care	718	735	(2%)	(4%)	310	348	(11%)	408	387	5%	2%
Specialty Care	\$ 3,130	\$ 3,003	4%	2%	\$ 1,623	\$ 1,688	(4%)	\$ 1,507	\$ 1,316	15%	10%
Vyndaqel family ^(c)	1,591	1,447	10%	7%	948	960	(1%)	643	486	32%	25%
Xeljanz	313	321	(3%)	(4%)	205	203	1%	108	118	(9%)	(13%)
Zavicefta (Outside the U.S. and Canada)	158	152	5%	3%	—	—	—	158	152	5%	3%
Enbrel (Outside the U.S. and Canada)	154	169	(9%)	(12%)	—	—	—	154	169	(9%)	(12%)
Genotropin	128	119	7%	6%	31	27	14%	97	92	5%	3%
Octagam	113	221	(49%)	(49%)	113	221	(49%)	—	—	—	—
Cresamba	83	67	23%	17%	—	—	—	83	67	23%	17%
Cibinqo	79	63	26%	24%	30	23	34%	49	40	21%	18%
All other Specialty Care	510	445	15%	14%	294	253	16%	216	192	13%	11%
Oncology	\$ 3,938	\$ 3,758	5%	4%	\$ 2,888	\$ 2,850	1%	\$ 1,051	\$ 909	16%	11%
Ibrance	1,057	1,087	(3%)	(5%)	670	717	(7%)	387	371	4%	(1%)
Xtandi ⁽ⁱ⁾	578	561	3%	3%	578	561	3%	—	—	—	—
Padcev	464	409	13%	13%	449	407	10%	16	2	*	*
Lorbrena	268	206	30%	28%	103	82	25%	165	124	34%	30%
Inlyta	226	247	(8%)	(9%)	124	150	(17%)	102	97	6%	3%
Adcetris ^(g)	215	268	(20%)	(20%)	210	260	(19%)	5	8	(37%)	(37%)
Braňovi/Mektovi	202	173	17%	17%	190	165	15%	12	8	52%	53%
Bosulif	150	161	(7%)	(8%)	117	113	3%	34	48	(30%)	(33%)
Tukysa	110	124	(11%)	(12%)	79	97	(19%)	32	27	18%	11%
Aromasin	114	87	31%	30%	—	1	(41%)	114	87	32%	30%
Orgovyx ^(h)	112	57	97%	97%	112	57	97%	—	—	—	—
Elrexfo	85	40	*	*	37	26	40%	48	14	*	*
Talzenna	47	36	32%	30%	33	28	21%	14	8	70%	60%
Tivdak	37	34	8%	8%	32	32	(1%)	5	2	*	*
All other Oncology	272	268	1%	—	156	155	1%	116	114	2%	—
Hospital and Biosimilars^(a)	\$ 1,600	\$ 1,577	1%	—	\$ 745	\$ 660	13%	\$ 854	\$ 917	(7%)	(9%)
Oncology biosimilars ⁽ⁱ⁾	315	285	11%	10%	214	176	22%	101	109	(7%)	(10%)
Sulperazon (Outside the U.S. and Canada)	154	156	(2%)	(2%)	—	—	—	154	156	(2%)	(2%)
Inflectra	173	126	37%	37%	152	65	*	22	61	(65%)	(66%)
Zithromax	73	83	(13%)	(14%)	—	—	—	73	83	(13%)	(14%)
All other Hospital and Biosimilars	885	926	(4%)	(6%)	379	418	(9%)	506	507	—	(2%)
Pfizer CentreOne^(j)	\$ 344	\$ 285	21%	18%	\$ 92	\$ 76	21%	\$ 253	\$ 210	21%	17%
Pfizer Ignite	\$ —	\$ 25	(99%)	(99%)	\$ —	\$ 25	(99%)	\$ —	\$ —	—	—
Biopharma	\$ 16,310	\$ 17,392	(6%)	(7%)	\$ 10,599	\$ 11,964	(11%)	\$ 5,711	\$ 5,428	5%	2%
PFIZER U.S. COMMERCIAL DIVISION	9,854	11,304	(13%)	(13%)	9,854	11,304	(13%)	—	—	—	—
PFIZER INTERNATIONAL COMMERCIAL DIVISION	5,381	5,077	6%	2%	—	—	—	5,381	5,077	6%	2%
GLOBAL HOSPITAL AND BIOSIMILARS DIVISION ^(k)	1,075	1,011	6%	5%	745	660	13%	330	351	(6%)	(9%)
Total Alliance revenues included above	\$ 2,298	\$ 1,900	21%	19%	\$ 1,817	\$ 1,474	23%	\$ 481	\$ 427	13%	6%
Total Royalty revenues included above	\$ 436	\$ 384	13%	13%	\$ 434	\$ 383	13%	\$ 2	\$ 2	26%	24%

PFIZER INC. REVENUES
NINE MONTHS 2025 and 2024
UNAUDITED
(millions of dollars)

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL			
	2025	2024	% Change		2025	2024	% Change	2025	2024	% Change	
			Total	Oper.						Total	Total
TOTAL REVENUES	\$ 45,022	\$ 45,864	(2%)	(2%)	\$ 27,959	\$ 29,470	(5%)	\$ 17,063	\$ 16,394	4%	4%
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)^(a)	\$ 44,056	\$ 44,987	(2%)	(2%)	\$ 27,677	\$ 29,218	(5%)	\$ 16,379	\$ 15,769	4%	4%
Primary Care	\$ 18,869	\$ 21,208	(11%)	(11%)	\$ 12,349	\$ 14,799	(17%)	\$ 6,519	\$ 6,408	2%	2%
Eliquis ^(b)	5,941	5,534	7%	7%	3,913	3,677	6%	2,028	1,857	9%	8%
Prevnar family ^(c)	4,786	4,853	(1%)	(1%)	3,185	3,289	(3%)	1,601	1,564	2%	3%
Paxlovid ^(d)	2,144	4,989	(57%)	(57%)	1,796	4,181	(57%)	347	807	(57%)	(56%)
Comirnaty	2,097	1,970	6%	6%	1,275	1,339	(5%)	821	631	30%	30%
Nurtec ODT/Vydura	1,019	870	17%	17%	945	820	15%	74	50	49%	48%
Abrysvo	553	557	(1%)	—	374	490	(24%)	178	66	*	*
FSME-IMMUN/TicoVac	272	246	11%	8%	3	3	17%	269	244	10%	7%
All other Primary Care	2,058	2,188	(6%)	(5%)	858	999	(14%)	1,200	1,189	1%	2%
Specialty Care	\$ 8,834	\$ 8,230	7%	7%	\$ 4,551	\$ 4,451	2%	\$ 4,284	\$ 3,779	13%	13%
Vyndaqel family ^(c)	4,692	3,907	20%	19%	2,924	2,572	14%	1,767	1,334	32%	31%
Xeljanz	763	818	(7%)	(7%)	431	459	(6%)	331	360	(8%)	(8%)
Zavicefta (Outside the U.S. and Canada)	457	427	7%	9%	—	—	—	457	427	7%	9%
Enbrel (Outside the U.S. and Canada)	448	507	(12%)	(11%)	—	—	—	448	507	(12%)	(11%)
Genotropin	329	358	(8%)	(7%)	60	85	(30%)	269	272	(1%)	—
Octagam	298	400	(26%)	(26%)	298	400	(26%)	—	—	—	—
Cresamba	267	213	25%	24%	—	—	—	267	213	25%	24%
Cibinqo	206	152	36%	36%	79	61	28%	127	90	41%	41%
All other Specialty Care	1,376	1,449	(5%)	(4%)	759	874	(13%)	617	575	7%	9%
Oncology	\$ 11,467	\$ 10,720	7%	7%	\$ 8,537	\$ 8,003	7%	\$ 2,930	\$ 2,717	8%	8%
Ibrance	3,083	3,272	(6%)	(6%)	2,024	2,136	(5%)	1,058	1,135	(7%)	(8%)
Xtandi ⁽ⁱ⁾	1,602	1,474	9%	9%	1,602	1,474	9%	—	—	—	—
Padcev	1,432	1,144	25%	25%	1,402	1,128	24%	30	16	88%	89%
Lorbrena	741	538	38%	38%	294	211	39%	447	327	37%	37%
Inlyta	688	736	(7%)	(6%)	385	442	(13%)	303	294	3%	4%
Adcetris ^(g)	687	804	(15%)	(14%)	671	784	(14%)	16	20	(21%)	(18%)
Braňovi/Mektovi	519	437	19%	19%	489	417	17%	30	20	55%	61%
Bosulif	450	474	(5%)	(5%)	353	333	6%	97	141	(31%)	(32%)
Tukysa	344	351	(2%)	(2%)	269	283	(5%)	76	68	11%	9%
Aromasin	333	257	30%	30%	1	2	(25%)	332	255	30%	31%
Orgovyx ^(h)	285	136	*	*	285	136	*	—	—	—	—
Elrexfo	230	76	*	*	102	55	85%	128	20	*	*
Talzenna	133	91	47%	46%	96	69	39%	37	21	74%	71%
Tivdak	115	94	23%	22%	106	92	15%	10	2	*	*
All other Oncology	824	837	(2%)	(1%)	458	440	4%	366	397	(8%)	(7%)
Hospital and Biosimilars^(a)	\$ 4,886	\$ 4,829	1%	2%	\$ 2,240	\$ 1,964	14%	\$ 2,646	\$ 2,865	(8%)	(6%)
Oncology biosimilars ⁽ⁱ⁾	932	828	13%	13%	648	512	27%	284	316	(10%)	(9%)
Sulperazon (Outside the U.S. and Canada)	484	468	3%	4%	—	—	—	484	468	3%	4%
Inflectra	465	382	22%	23%	354	205	73%	111	177	(38%)	(36%)
Zithromax	286	357	(20%)	(19%)	—	1	(71%)	286	357	(20%)	(19%)
All other Hospital and Biosimilars	2,719	2,794	(3%)	(2%)	1,237	1,247	(1%)	1,482	1,547	(4%)	(3%)
Pfizer CentreOne^(j)	\$ 929	\$ 820	13%	13%	\$ 245	\$ 195	25%	\$ 684	\$ 625	9%	9%
Pfizer Ignite	\$ 37	\$ 56	(34%)	(34%)	\$ 37	\$ 56	(34%)	\$ —	\$ —	—	—
Biopharma	\$ 44,056	\$ 44,987	(2%)	(2%)	\$ 27,677	\$ 29,218	(5%)	\$ 16,379	\$ 15,769	4%	4%
PFIZER U.S. COMMERCIAL DIVISION	25,437	27,254	(7%)	(7%)	25,437	27,254	(7%)	—	—	—	—
PFIZER INTERNATIONAL COMMERCIAL DIVISION	15,408	14,699	5%	5%	—	—	—	15,408	14,699	5%	5%
GLOBAL HOSPITAL AND BIOSIMILARS DIVISION ^(k)	3,211	3,034	6%	6%	2,240	1,964	14%	971	1,070	(9%)	(8%)
Total Alliance revenues included above	\$ 6,684	\$ 6,140	9%	9%	\$ 5,381	\$ 4,935	9%	\$ 1,304	\$ 1,205	8%	6%
Total Royalty revenues included above	\$ 1,170	\$ 992	18%	18%	\$ 1,162	\$ 989	18%	\$ 8	\$ 4	*	*

PFIZER INC. REVENUES
FOURTH QUARTER 2025 and 2024
UNAUDITED
(millions of dollars)

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL			
	2025	2024	% Change		2025	2024	% Change	2025	2024	% Change	
			Total	Oper.						Total	Total
TOTAL REVENUES	\$ 17,557	\$ 17,763	(1%)	(3%)	\$ 9,119	\$ 9,221	(1%)	\$ 8,438	\$ 8,542	(1%)	(4%)
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)^(a)	\$ 17,144	\$ 17,413	(2%)	(3%)	\$ 9,031	\$ 9,114	(1%)	\$ 8,113	\$ 8,299	(2%)	(5%)
Primary Care	\$ 7,932	\$ 8,904	(11%)	(13%)	\$ 3,546	\$ 3,982	(11%)	\$ 4,387	\$ 4,922	(11%)	(14%)
Eliquis ^(b)	2,020	1,832	10%	8%	1,235	1,126	10%	785	705	11%	4%
Prevnar family ^(c)	1,708	1,558	10%	8%	966	944	2%	742	614	21%	18%
Comirnaty	2,271	3,383	(33%)	(35%)	387	665	(42%)	1,883	2,718	(31%)	(33%)
Paxlovid	218	727	(70%)	(70%)	95	435	(78%)	123	293	(58%)	(59%)
Nurtec ODT/Vydura	405	392	3%	3%	377	373	1%	27	20	40%	35%
Abrysvo	481	198	*	*	168	104	61%	313	94	*	*
FSME-IMMUN/TicoVac	47	34	38%	29%	—	—	—	47	34	39%	29%
All other Primary Care	783	779	—	(1%)	316	335	(6%)	467	444	5%	2%
Specialty Care	\$ 3,361	\$ 3,040	11%	8%	\$ 1,606	\$ 1,582	2%	\$ 1,755	\$ 1,458	20%	16%
Vyndaqel family ^(c)	1,688	1,545	9%	7%	910	975	(7%)	778	570	37%	30%
Xeljanz	324	349	(7%)	(8%)	194	221	(13%)	131	128	2%	(1%)
Zavicefta (Outside the U.S. and Canada)	181	159	14%	10%	—	—	—	181	159	14%	10%
Enbrel (Outside the U.S. and Canada)	180	183	(2%)	(5%)	—	—	—	180	183	(2%)	(5%)
Genotropin	117	112	5%	2%	19	10	81%	98	101	(3%)	(6%)
Octagam	120	109	10%	10%	120	109	10%	—	—	—	—
Cresamba	83	67	23%	17%	—	—	—	83	67	23%	17%
Cibinqo	78	64	23%	22%	37	29	28%	42	35	19%	17%
All other Specialty Care	590	451	31%	30%	327	238	38%	263	213	23%	21%
Oncology	\$ 4,066	\$ 3,855	5%	5%	\$ 3,061	\$ 2,936	4%	\$ 1,004	\$ 919	9%	6%
Ibrance	1,040	1,095	(5%)	(7%)	686	713	(4%)	354	382	(7%)	(12%)
Xtandi ⁽ⁱ⁾	592	565	5%	5%	592	565	5%	—	—	—	—
Padcev	508	444	15%	15%	500	433	16%	8	11	(24%)	(23%)
Lorbrena	282	192	46%	45%	112	95	18%	169	97	74%	70%
Inlyta	235	242	(3%)	(4%)	131	145	(10%)	104	97	8%	6%
Adcetris ^(g)	220	285	(23%)	(23%)	213	276	(23%)	6	9	(33%)	(31%)
Braňovi/Mektovi	197	170	16%	16%	183	163	12%	14	7	99%	97%
Bosulif	161	171	(6%)	(6%)	135	128	6%	26	44	(39%)	(40%)
Tukysa	119	129	(8%)	(9%)	84	106	(21%)	35	23	55%	47%
Aromasin	117	90	30%	30%	1	1	(12%)	116	89	30%	30%
Orgovyx ^(h)	136	64	*	*	136	64	*	—	—	—	—
Elrexfo	74	57	30%	30%	41	32	26%	33	25	34%	37%
Talzenna	49	27	83%	80%	36	18	97%	13	9	51%	43%
Tivdak	32	36	(13%)	(12%)	34	34	—	(2)	2	*	*
All other Oncology	303	286	6%	5%	178	163	9%	126	123	2%	—
Hospital and Biosimilars^(a)	\$ 1,784	\$ 1,614	11%	10%	\$ 817	\$ 613	33%	\$ 967	\$ 1,001	(3%)	(5%)
Oncology biosimilars ⁽ⁱ⁾	369	209	77%	76%	266	116	*	104	93	11%	8%
Sulperazon (Outside the U.S. and Canada)	169	170	—	—	—	—	—	169	170	—	—
Inflectra	181	127	42%	42%	157	64	*	24	64	(63%)	(63%)
Zithromax	113	122	(7%)	(8%)	—	—	—	113	122	(7%)	(8%)
All other Hospital and Biosimilars	952	986	(3%)	(4%)	394	434	(9%)	557	552	1%	(1%)
Pfizer CentreOne^(j)	\$ 409	\$ 325	26%	22%	\$ 84	\$ 82	2%	\$ 325	\$ 243	34%	29%
Pfizer Ignite	\$ 4	\$ 26	(83%)	(83%)	\$ 4	\$ 26	(83%)	\$ —	\$ —	—	—
Biopharma	\$ 17,144	\$ 17,413	(2%)	(3%)	\$ 9,031	\$ 9,114	(1%)	\$ 8,113	\$ 8,299	(2%)	(5%)
PFIZER U.S. COMMERCIAL DIVISION	8,214	8,501	(3%)	(3%)	8,214	8,501	(3%)	—	—	—	—
PFIZER INTERNATIONAL COMMERCIAL DIVISION	7,749	7,926	(2%)	(5%)	—	—	—	7,749	7,926	(2%)	(5%)
GLOBAL HOSPITAL AND BIOSIMILARS DIVISION ^(k)	1,181	986	20%	19%	817	613	33%	364	373	(2%)	(5%)
Total Alliance revenues included above	\$ 2,582	\$ 2,248	15%	14%	\$ 1,828	\$ 1,641	11%	\$ 753	\$ 607	24%	19%
Total Royalty revenues included above	\$ 480	\$ 431	11%	11%	\$ 477	\$ 429	11%	\$ 3	\$ 2	52%	48%

PFIZER INC. REVENUES
TWELVE MONTHS 2025 and 2024
UNAUDITED
(millions of dollars)

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL			
	2025	2024	% Change		2025	2024	% Change	2025	2024	% Change	
			Total	Oper.						Total	Total
TOTAL REVENUES	\$ 62,579	\$ 63,627	(2%)	(2%)	\$ 37,078	\$ 38,691	(4%)	\$ 25,501	\$ 24,936	2%	1%
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)^(a)	\$ 61,199	\$ 62,400	(2%)	(2%)	\$ 36,708	\$ 38,332	(4%)	\$ 24,491	\$ 24,068	2%	1%
Primary Care	\$ 26,801	\$ 30,112	(11%)	(12%)	\$ 15,895	\$ 18,781	(15%)	\$ 10,906	\$ 11,330	(4%)	(5%)
Eliquis ^(b)	7,961	7,366	8%	7%	5,148	4,803	7%	2,813	2,563	10%	7%
Prevnar family ^(c)	6,494	6,411	1%	1%	4,151	4,233	(2%)	2,342	2,178	8%	7%
Comirnaty	4,367	5,353	(18%)	(20%)	1,663	2,004	(17%)	2,705	3,349	(19%)	(21%)
Paxlovid ^(d)	2,362	5,716	(59%)	(59%)	1,891	4,616	(59%)	470	1,100	(57%)	(57%)
Nurtec ODT/Vydura	1,424	1,263	13%	13%	1,322	1,193	11%	102	69	46%	44%
Abrysvo	1,033	755	37%	36%	542	594	(9%)	491	160	*	*
FSME-IMMUN/TicoVac	319	280	14%	10%	3	3	13%	316	277	14%	10%
All other Primary Care	2,841	2,968	(4%)	(4%)	1,174	1,335	(12%)	1,667	1,633	2%	2%
Specialty Care	\$ 12,196	\$ 11,270	8%	8%	\$ 6,157	\$ 6,034	2%	\$ 6,038	\$ 5,236	15%	14%
Vyndaqel family ^(e)	6,380	5,451	17%	16%	3,834	3,547	8%	2,546	1,904	34%	30%
Xeljanz	1,087	1,168	(7%)	(7%)	625	680	(8%)	462	488	(5%)	(6%)
Zavicefta (Outside the U.S. and Canada)	638	586	9%	9%	—	—	—	638	586	9%	9%
Enbrel (Outside the U.S. and Canada)	627	690	(9%)	(9%)	—	—	—	627	690	(9%)	(9%)
Genotropin	446	470	(5%)	(5%)	79	96	(18%)	367	374	(2%)	(1%)
Octagam	418	509	(18%)	(18%)	418	509	(18%)	—	—	—	—
Cresamba	349	281	24%	22%	—	—	—	349	281	24%	22%
Cibinqo	284	215	32%	32%	115	90	28%	169	126	35%	34%
All other Specialty Care	1,966	1,900	3%	4%	1,087	1,112	(2%)	880	788	12%	12%
Oncology	\$ 15,532	\$ 14,575	7%	6%	\$ 11,598	\$ 10,939	6%	\$ 3,934	\$ 3,636	8%	7%
Ibrance	4,122	4,367	(6%)	(6%)	2,710	2,849	(5%)	1,412	1,518	(7%)	(9%)
Xtandi ^(f)	2,194	2,039	8%	8%	2,194	2,039	8%	—	—	—	—
Padcev	1,940	1,588	22%	22%	1,902	1,561	22%	38	27	42%	43%
Lorbrena	1,023	731	40%	40%	407	306	33%	616	424	45%	44%
Inlyta	923	978	(6%)	(6%)	516	588	(12%)	407	391	4%	4%
Adcetris ^(g)	907	1,089	(17%)	(17%)	885	1,059	(16%)	23	30	(25%)	(23%)
Braftovi/Mektovi	716	607	18%	18%	672	580	16%	45	27	67%	71%
Bosulif	611	645	(5%)	(5%)	488	460	6%	124	185	(33%)	(34%)
Tukysa	463	480	(4%)	(4%)	352	389	(10%)	111	91	22%	18%
Aromasin	450	347	30%	30%	2	2	(21%)	448	345	30%	30%
Orgovyx ^(h)	421	201	*	*	421	201	*	—	—	—	—
Elrexfo	304	133	*	*	143	88	63%	161	45	*	*
Talzenna	182	117	55%	54%	133	88	51%	50	30	67%	63%
Tivdak	147	131	13%	13%	140	126	11%	7	5	59%	59%
All other Oncology	1,127	1,122	—	1%	635	603	5%	492	519	(5%)	(5%)
Hospital and Biosimilars^(a)	\$ 6,671	\$ 6,443	4%	4%	\$ 3,057	\$ 2,577	19%	\$ 3,613	\$ 3,865	(7%)	(6%)
Oncology biosimilars ⁽ⁱ⁾	1,301	1,037	25%	26%	914	628	46%	387	409	(5%)	(5%)
Sulperazon (Outside the U.S. and Canada)	653	637	2%	3%	—	—	—	653	637	2%	3%
Inflectra	646	509	27%	27%	511	268	91%	134	241	(44%)	(43%)
Zithromax	399	480	(17%)	(16%)	—	1	(66%)	399	479	(17%)	(16%)
All other Hospital and Biosimilars	3,671	3,780	(3%)	(2%)	1,631	1,681	(3%)	2,039	2,099	(3%)	(2%)
Pfizer CentreOne^(j)	\$ 1,338	\$ 1,146	17%	15%	\$ 329	\$ 278	18%	\$ 1,010	\$ 868	16%	15%
Pfizer Ignite	\$ 41	\$ 82	(50%)	(50%)	\$ 41	\$ 82	(50%)	\$ —	\$ —	—	—
Biopharma	\$ 61,199	\$ 62,400	(2%)	(2%)	\$ 36,708	\$ 38,332	(4%)	\$ 24,491	\$ 24,068	2%	1%
PFIZER U.S. COMMERCIAL DIVISION	33,651	35,754	(6%)	(6%)	33,651	35,754	(6%)	—	—	—	—
PFIZER INTERNATIONAL COMMERCIAL DIVISION	23,157	22,625	2%	1%	—	—	—	23,157	22,625	2%	1%
GLOBAL HOSPITAL AND BIOSIMILARS DIVISION ^(k)	4,392	4,020	9%	9%	3,057	2,577	19%	1,335	1,443	(8%)	(7%)
Total Alliance revenues included above	\$ 9,266	\$ 8,388	10%	10%	\$ 7,209	\$ 6,575	10%	\$ 2,057	\$ 1,813	13%	11%
Total Royalty revenues included above	\$ 1,650	\$ 1,423	16%	16%	\$ 1,639	\$ 1,418	16%	\$ 11	\$ 6	94%	91%

PFIZER INC.
NOTES TO REVENUES TABLE INFORMATION
(UNAUDITED)

- (a) In the first quarter of 2026, we made changes in our commercial structure, which included the transition of certain off-patent branded and generic sterile injectables and biosimilars primarily from the Specialty Care and Oncology product portfolios to a new Hospital and Biosimilars product portfolio within our Biopharma reportable segment. Effective January 1, 2026, the commercial structure within the Biopharma reportable segment is composed of the Pfizer U.S. Commercial Division, the Pfizer International Commercial Division and the Global Hospital and Biosimilars Division. The amounts presented in the 2025 Product Revenues Tables have been recasted to conform to Pfizer's new commercial operating structure. For additional information regarding our commercial organizational structure, see the Item 1. Business—Commercial Operations section of our 2025 Annual Report on Form 10-K (available at www.pfizer.com).
 - (b) Reflects alliance revenues and product revenues.
 - (c) Prevnar family includes revenues from Prevnar 20/Prevenar 20 (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult).
 - (d) 2024 included a \$771 million favorable final adjustment recorded in the first quarter of 2024 to the estimated non-cash revenue reversal of \$3.5 billion recorded in the fourth quarter of 2023, reflecting 5.1 million emergency use authorization-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated 6.5 million treatment courses that were expected to be returned as of December 31, 2023. 2024 also included \$442 million of revenue recorded in the third quarter of 2024 in connection with the creation of a U.S. Strategic National Stockpile of 1.0 million treatment courses, which we supplied at no cost to the U.S. government or taxpayers.
 - (e) Vyndaqel family includes global revenues from Vyndaqel, as well as revenues for Vyndamax in the U.S. and Vynmac in Japan.
 - (f) Primarily reflects alliance revenues and royalty revenues.
 - (g) Reflects product revenues and royalty revenues.
 - (h) Reflects alliance revenues.
 - (i) Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Ruxience, Retacrit, Zirabev, Trazimera and Nivestym.
 - (j) Pfizer CentreOne (PC1) includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships.
 - (k) Includes the commercial organization covering Pfizer's Hospital and Biosimilars product portfolio of off-patent branded and generic sterile injectables and biosimilars except in China, Hong Kong, and certain other international markets, which are part of the Pfizer International Commercial Division.
- * Indicates calculation not meaningful or results are greater than 100%.
Amounts may not add due to rounding. All percentages have been calculated using unrounded amounts.